Adaptive Biotechnologies (ADPT) Gross Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed Gross Margin across 9 years of filings, most recently posting 73.6% for Q1 2026.

• Gross Margin for Q1 2026 came in at 73.6%, up 598.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 75.26% (up 1716.0% YoY), and the FY2025 annual result was 74.24%, up 2160.0% from the prior year.
• Gross Margin came in at 73.6% for Q1 2026 at Adaptive Biotechnologies, down from 74.58% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 80.68% in Q3 2025 to a low of 210.03% in Q2 2023.
• The 5-year median for Gross Margin is 56.89% (2024), against an average of 45.31%.
• Across the five-year window, Gross Margin plunged 27974 bps in 2023 and jumped 26299 bps in 2024, its largest moves.
• Adaptive Biotechnologies' Gross Margin stood at 57.03% in 2022, then jumped by 41 bps to 80.6% in 2023, then sank by 32 bps to 54.54% in 2024, then surged by 37 bps to 74.58% in 2025, then retreated by 1 bps to 73.6% in 2026.
• The last three Gross Margin figures came in at 73.6% (Q1 2026), 74.58% (Q4 2025), and 80.68% (Q3 2025), per Business Quant data.